DUBAI, UAE, March 9, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, today announced the appointment of Derek Dai as Country Manager for the Middle East and North Africa (MENA), reinforcing the company’s long-term commitment to the United Arab Emirates as a strategic hub for digital asset innovation.

In this role, Derek will lead Bybit’s regional strategy across MENA, overseeing market expansion, regulatory collaboration, institutional partnerships, and localized product development as the company continues to strengthen its regulated footprint following its recent Securities and Commodities Authority (SCA) license.

“The UAE gave Bybit a home. You do not abandon your home when the storm comes — you stand in the doorway,” said Helen Liu, co-CEO of Bybit. “Some companies are reassessing their Gulf exposure right now. We are doing the opposite. We are deepening our presence, our investment, and our commitment to this region.”

Bybit’s appointment of Derek comes at a pivotal moment for the region — a decision made not despite the current geopolitical uncertainty, but because of it.

A Strategic Moment for the Middle East

“The Middle East is emerging as one of the most important regions shaping the future of digital finance, with the UAE leading the way in building a progressive and well-regulated ecosystem,” said Derek Dai, Country Manager for MENA at Bybit.

“Our priority is to deepen collaboration with financial centers such as DIFC and DMCC, while strengthening the infrastructure that connects digital assets with everyday financial services and advancing the development of tokenized real-world assets that bridge traditional finance and the digital asset economy.”

“In the coming months, we will focus on expanding AED fiat access, building partnerships with banks and payment providers, and enhancing our Islamic finance offerings through the development of more Shariah-compliant products,” Derek added. “By working closely with regulators, institutions, and builders, we aim to support the next phase of responsible digital asset adoption across the Middle East, while expanding our presence across the GCC, with Bahrain representing one of the next key milestones for Bybit in the region.”

Building Long-Term Roots in the UAE

Bybit views the UAE not only as a market, but as a strategic bridge between traditional financial systems and the emerging digital asset economy.

As part of its commitment to the local community, the company partnered with the Emirates Red Crescent during Ramadan to support the Iftar Tent initiative, providing meals throughout the holy month and organizing employee volunteer activities to assist families and individuals in need.

Amid the recent geopolitical tensions in the Middle East, Bybit has also taken proactive steps to ensure the safety and well-being of its UAE-based employees while maintaining stable services for its global users. The company activated comprehensive Business Continuity Protocols (BCP) across its Dubai and Abu Dhabi operations, introducing daily management check-ins, real-time employee safety confirmations, and relocation or travel assistance for staff in sensitive areas.

“Bybit’s commitment to the UAE was made for the long term — through growth and through adversity,” said Helen. “We continue to invest in local talent, regulatory compliance, and community partnerships. The UAE’s vision to become the world’s leading digital asset hub is not diminished by this crisis. If anything, the resilience this nation is showing only reinforces why we chose to build here.”

“Our users in the UAE, Saudi Arabia, Qatar, and across the Gulf need to know one thing: Bybit is open, Bybit is liquid, and Bybit is staffed around the clock,” Derek added. “Your funds are safe. Your access is uninterrupted. We are not going offline, and we are not leaving.”

A Message to the UAE Community

“To our entire UAE family — our users, our partners, our colleagues, and every family across the Emirates — Bybit stands with you,” said Helen Liu. “We wish safety, strength, and peace to everyone affected by this conflict. The UAE has shown the world what courage and resilience look like, and we are honored to stand alongside this community. We are here today, we will be here tomorrow, and we will be here long after this crisis passes.”

#Bybit / #TheCryptoArk

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

• Over 40 AI models lightweighted and optimized across more than 100 devices; technologies adopted by global leaders including Samsung and NVIDIA
• Live demonstrations of LLM and computer vision models running in real time on Qualcomm and Arm hardware, alongside a Device Farm exhibit showcasing edge AI optimization capabilities
• Real-world applications of NVA (Nota Vision Agent) in safety, security, and smart city operations; VLA research recognized at ICLR and AAAI highlights Nota’s technological leadership

SEOUL, South Korea, March 9, 2026 /PRNewswire/ — Nota AI, an AI optimization technology company, announced that it will participate in Embedded World 2026, taking place March 10-12 in Nuremberg, Germany. At the event, the company will present the full lifecycle of on-device AI-from model optimization to deployment in real-world industrial environments.

Embedded World is one of the world’s largest exhibitions and conferences dedicated to embedded systems, bringing together approximately 1,000 exhibitors and more than 30,000 industry professionals. Global semiconductor, software, and mobility companies including AMD, Intel, and Qualcomm participate in the event. Through its exhibition, Nota AI will showcase how AI models are optimized through NetsPresso® and deployed across a wide range of global hardware platforms before being implemented in real industrial environments.

At the event, Nota AI will demonstrate how semiconductor companies can rapidly optimize high-performance AI models for their chips using its AI model optimization platform, NetsPresso®. The company has accumulated extensive expertise in lightweighting and optimizing AI models—from small language models (SLMs) to large language models (LLMs) and vision-language models (VLMs). To date, Nota AI has successfully compressed more than 40 AI models while maintaining performance and has deployed its optimization technologies across over 100 hardware devices.

Nota AI’s AI lightweighting and optimization technologies have already been recognized in the global market. The company recently supplied AI optimization technology for Samsung Electronics’ Exynos 2600, where the technology serves as a core component enabling mobile on-device AI capabilities. Nota AI has also maintained ongoing technology collaborations with global semiconductor companies including Qualcomm and Arm. At Embedded World, the company will present live demonstrations showing both computer vision models and large language models running in real time on these hardware platforms, highlighting AI performance in edge environments.

Nota AI will also showcase a Device Farm, featuring a collection of hardware platforms optimized by the company over the past decade. Visitors will be able to explore a range of chipsets from major global semiconductor companies running AI models optimized with Nota AI’s technology, demonstrating the company’s experience in optimizing more than 100 hardware platforms over the past ten years.

In addition, Nota AI will introduce real-world solutions that combine AI models with hardware optimization in on-device environments. Through its video analytics solution NVA (Nota Vision Agent), Nota AI has delivered technologies across industries such as safety monitoring, security, and smart city operations in collaboration with global partners including NVIDIA. At the booth, the company will demonstrate real deployment cases including selective video monitoring, intelligent transportation systems (ITS), and industrial safety monitoring.

Nota AI will also present its latest research achievements recently accepted at ICLR 2026 and the AAAI 2026 Foundation Model Workshop. Both studies focus on improving the efficiency and reliability of vision-language models (VLMs), highlighting Nota AI’s technological capabilities across the broader physical AI landscape-from vision-language models to vision-language-action (VLA) systems.

During the exhibition, Tae-Ho Kim, CTO & Co-Founder of Nota AI, will host mini sessions at the booth to present the company’s AI lightweighting and optimization strategies and share real-world cases of applying Nota AI technologies to global semiconductor platforms. The sessions will provide insights into Nota AI’s approach to efficiently running AI models on edge devices and the company’s technological differentiation.

“Nota AI has continuously advanced lightweighting and optimization technologies that enable AI models to run efficiently across more than 100 types of hardware without being limited to a single device architecture,” said Myungsu Chae, CEO of Nota AI. “Through Embedded World, we look forward to sharing how our technologies operate across diverse global hardware environments and how they are being applied in real industrial settings.”

Nota AI will offer complimentary Embedded World visitor passes to attendees who pre-register through the company’s official website and visit the Nota booth (Hall 5, Booth 5-422).

• Robots deployed across assembly, inspection, and riveting processes; expanded order secured following zero-defect achievement
• Companies to extend collaboration to additional production lines and co-develop customized automation solutions

SEONGNAM, South Korea, March 9, 2026 /PRNewswire/ — Doosan Robotics announced it will supply more than 100 manufacturing robot solutions to Kwangjin Group, a global automotive components manufacturer, under a strategic partnership.

Doosan Robotics announced on March 9 that it has signed a Memorandum of Understanding (MOU) with Kwangjin Group at Bundang Doosan Tower in Seongnam, Korea. Through this agreement, the two companies will collaborate on manufacturing process automation and strengthen quality competitiveness by deploying Doosan robot solutions.

Kwangjin Group specializes in automotive door system components and operates production facilities in key global markets, including the United States, Mexico, India, and Vietnam. Its major customers include leading global automakers such as General Motors, Ford Motor Company, Navistar, Volkswagen, Hyundai Motor, and Honda. Kwangjin Group has already integrated Doosan Robotics’ solutions into the riveting, assembly, and inspection processes of its window regulator and door module production lines.

Under the agreement, Doosan Robotics will sequentially supply more than 100 manufacturing robot solutions to Kwangjin Group’s domestic and overseas plants through 2027.

The expanded supply agreement represents formal validation of Doosan Robotics’ technological capabilities and reliability within the global automotive supply chain. Notably, following the deployment of Doosan’s manufacturing robot solutions, product defect rates were reduced to zero — an achievement that played a decisive role in securing the large-scale follow-up order.

Doosan Robotics’ manufacturing solutions can be implemented without modifications to existing factory layouts. They offer high levels of safety and precision, enabling effective human-robot collaboration. By minimizing quality variations caused by differences in operator skill levels, the solutions deliver consistent quality and meaningful defect reduction. In addition, they shorten production cycle times, enhance overall productivity, and support stable plant operations.

Building on this partnership, the two companies plan to expand their collaboration beyond large-scale deployment by jointly developing customized robot solutions tailored to additional component manufacturing processes. A joint task force will also be established to develop phased implementation strategies and optimize production environments for robot integration.

Inwon Park, CEO of Doosan Robotics, stated, “This agreement reflects the strong trust placed in our robot solutions, particularly following the achievement of a zero-defect rate, which directly led to this expanded partnership. We will ensure the successful deployment of our solutions across Kwangjin Group’s production facilities and further strengthen our position in the global automation market through close collaboration.”

Following its Best of Innovation award in the AI category at CES 2026 for its AI Sanding solution, Doosan Robotics is broadening its portfolio of safe, high-productivity AI robot solutions while accelerating R&D to lead the next wave of manufacturing innovation.

ABOUT DOOSAN ROBOTICS

Doosan Robotics is a global leader in collaborative robot solutions, delivering cutting-edge AI robotics to 45 countries worldwide. Renowned for world-class safety and performance, Doosan Robotics serves blue-chip customers across various industries, including automotive, electronics, semiconductor, logistics, and energy. More information about Doosan Robotics is available at https://www.doosanrobotics.com/en/.

CHENGDU, China, March 9, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of atopic dermatitis.

Atopic dermatitis is a chronic, inflammatory skin disease characterized by persistent itching, redness, and irritation. It affects around 20% of children and up to 10% of adults worldwide^[1]. Though not infectious, atopic dermatitis has a profound impact on patients’ quality of life due to its cyclical nature of flare-ups and remissions. Current treatments, including topical corticosteroids, biologics, and Janus kinase (JAK) inhibitors, provide symptomatic relief for many patients, but often fail to deliver sustained disease control, especially in moderate-to-severe cases. Therefore, there is an urgent need for safer, more effective, and durable treatments that address underlying disease mechanisms and improve long-term outcomes.

Dr. Michael Ge, CEO of Kelun-Biotech, stated: “We are delighted to see the approval of SKB575/HBM7575 for clinical trials in atopic dermatitis. This marks an important milestone in our strategic expansion in the field of autoimmune diseases and holds promise for offering a novel therapeutic option to patients with atopic dermatitis. As a bispecific antibody with a differentiated innovative mechanism and a long-acting profile, SKB575/HBM7575 holds the potential to deliver durable and stable disease control while improving patient treatment experience through reduced dosing frequency.”

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “The NMPA’s IND approval for HBM7575/SKB575 marks an important step forward in addressing the significant unmet needs in autoimmune diseases such as atopic dermatitis. By targeting TSLP, a key upstream driver of type 2 inflammation, and an undisclosed target, HBM7575/SKB575 has the potential to be a best-in-class bispecific antibody for this disease. We look forward to advancing this investigational therapy through clinical development and believe its long-acting profile may offer a differentiated treatment option for patients worldwide.”

About SKB575/HBM7575

SKB575/HBM7575 is a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, overcoming resistance issues associated with TSLP single-target antibodies. SKB575/HBM7575 has been engineered to possess an extended half-life and favorable developability, enabling subcutaneous administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy.

According to the collaboration agreement between the Company and Harbour BioMed, SKB575/HBM7575 is led by Kelun-Biotech in its design, global development and commercialization, with Harbour BioMed participating in the investment and development of this asset and sharing the benefits as agreed.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice^®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA^TM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice^®, HBICE^®, and HBICA^TM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

VICTORIA, Seychelles, March 9, 2026 /PRNewswire/ — MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true zero-fee trading, today released its January-February 2026 security report. The data underscores how operational rigor in asset protection and regulatory compliance translates into measurable institutional trust.

The report documents 34 successful fraud blocks totaling $4.09 million, with 26 cases progressing through judicial channels. Activity originated from coordinated rings in CIS, East Asia, and SEA—all identified and restricted before assets moved. MEXC also processed 924 user recovery claims, returning 553,228 USDT in mistaken transfers.

MEXC maintains substantial reserve ratios across all major assets: Bitcoin reserves exceed user holdings by 266%, while Ethereum, USDT, and USDC maintain coverage of 112%, 117%, and 124% respectively. These figures are published in real time and independently verifiable through on-chain proof-of-reserves. The $100 million Guardian Fund and Futures Insurance Fund—which absorbs liquidation losses in derivatives trading—remained fully operational and transparently queryable by all market participants.

The report underscores MEXC’s commitment toward structured, verifiable security disclosures. Fraud interception data, reserve ratios, and fund status are published consistently, allowing users and institutional investors to track exchange health across two-month periods.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.

MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ — With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin – a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex Colostrum Protein Isolate IgHM. In particular, IgHM is a specialised ingredient comprising a group of  antibodies structurally similar to those in breast milk. This is considered a breakthrough in the field of immunonutrition, promising to be a natural and superior source of immunonutrition.

So, What is IgHM?

For decades, medical professionals have dubbed breast milk the “gold standard” of early-life nutrition. Beyond basic calories, it acts as a sophisticated immune ecosystem, delivering a complex array of antibodies and bioactive compounds that shield infants from pathogens.

Researchers looking to replicate these benefits have long turned to bovine colostrum due to its high concentrations of IgG antibodies and immune-active proteins similar to those found in human milk, such as lactoferrin and lysozyme.

With advanced selection technology, scientists can now isolate specific protein structures from bovine colostrum that are structurally analogous to those in breast milk. This has enabled the development of IgHM (Immunoglobulin – like Human Milk) – a specialized ingredient comprising a group of antibodies structurally similar to those in human milk. Experts suggest this advancement represents a breakthrough in immunonutrition, offering a naturally derived source of immune support with targeted efficacy.

How is IgHM selected?

To isolate the IgHM antibody group, the manufacturer employs an advanced protein-selection process carried out in three key stages:

Step 1: Protein Structure Indentification

A proprietary technology platform maps and compiles a comprehensive Big Data – database of the three-dimensional protein structures found in both human milk and bovine colostrum. This big-data approach establishes the scientific foundation for identifying structural commonalities between the two nutritional sources.

Step 2: Proprietary Antibody Protein Filtration

Using a high-precision filtration system, protein molecules in bovine colostrum that exhibit the closest three-dimensional structural similarity to antibodies in human milk are selectively retained. This step ensures that only proteins with optimal structural alignment and biological activity are preserved.

Step 3: Biological Reference

After filtration, the selected antibodies undergo further compatibility testing with receptors in the gastrointestinal tract. The results are then referenced against breast milk data to confirm safety and immunogenic efficacy before being incorporated into the final product.

IgHM Application in Nutritional Products

With its assured natural origin and a selection process guided by breast milk data, IgHM emerges as a promising ingredient to further strengthen distinctive immune-boosting nutritional complex in the new ColosBaby Lactoferrin formula. This development also reflects a close collaboration between a pioneering Vietnamese leader in immuno nutrition and cutting-edge scientific advancements worldwide, united by a shared commitment to applying nutritional science to nurture the health and development of Vietnamese children.

PETALING JAYA, Malaysia, March 9, 2026 /PRNewswire/ — Care Ventures Group (CVG) has announced a strategic investment in REN Health Sdn Bhd, positioning the company for its next phase as an AI-enabled women’s wellness platform.

REN develops herbal-based solutions targeting female-specific health concerns, including hormonal regulation, menstrual support, and postpartum recovery. With CVG’s investment, the company will transition beyond product distribution into a technology-led, data-driven wellness model built for scale.

Building Intelligent Infrastructure for Women’s Health

The investment will accelerate REN’s transformation into an AI-powered women’s wellness platform, leveraging predictive health intelligence, personalised herbal recommendations, and smart subscription technology to redefine convenience in female wellness.

Funding will support the development of:

• AI-based recommendation engines that adapt to user behaviour and health patterns
• Predictive cycle-aligned replenishment systems
• Automated subscription frameworks designed around hormonal rhythms and life stages
• Data analytics capabilities to enhance product matching accuracy and long-term engagement

At Care Ventures Group, we see AI as the backbone of the next generation of healthcare and wellness. Our investment in REN will accelerate the development of intelligent recommendation engines, predictive wellness tools, and smart subscription systems that personalise herbal support based on individual needs. This is not just about scaling products; it’s about scaling precision, convenience, and long-term health outcomes for women.

Leveraging Ecosystem Distribution for Rapid Scale

Beyond AI development, REN will leverage CVG’s expanding digital ecosystem and investment portfolio to fast-track market penetration.

Strategic alignment with complementary brands, including itsherbs.com, creates opportunities for cross-platform bundling, shared customer intelligence, and unified acquisition strategies.

By consolidating data, distribution, and consumer touchpoints, REN is positioned to scale faster than traditional product-led brands, transforming from a standalone offering into a connected node within a broader women’s wellness infrastructure.

About Care Ventures Group

Care Ventures Group is an investment holding company focused on acquiring and scaling businesses within the wellness and healthcare sector. The Group is committed to redefining how families access and experience care by integrating holistic wellness solutions with advanced digital technologies. Through data-driven platforms, personalised engagement systems and seamless health access tools, Care Ventures Group builds interconnected ecosystems that support long-term wellbeing. Its innovation-led approach empowers individuals and families to lead healthier, more balanced lives in an increasingly complex world.

About REN Health

REN Health Sdn Bhd is a women’s wellness brand evolving into a technology-enabled FemTech platform that blends traditional herbal expertise with data-informed personalisation. From its acclaimed 28-day Confinement Herbal Soup programme to other female-focused formulations, REN prioritises high-quality SGS-certified ingredients and thoughtful product design to support women’s wellbeing at every stage. With plans to integrate AI-powered recommendation systems and automated subscription services, REN aims to redefine convenience and long-term engagement in female health solutions.

Visit REN now at https://ren2health.com/